Drugs Made In America Acquisition II (NASDAQ:DMII) Stock Price Down 0.3% – Time to Sell?

Posted by Amy Steele on Feb 27th, 2026

Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Get Free Report) shares traded down 0.3% on Thursday . The company traded as low as $9.98 and last traded at $9.98. 1,393,300 shares traded hands during mid-day trading, an increase of 994% from the average session volume of 127,389 shares. The stock had previously closed at $10.01.

Drugs Made In America Acquisition II Price Performance

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of DMII. Magnetar Financial LLC bought a new stake in Drugs Made In America Acquisition II during the 4th quarter worth $26,730,000. Glazer Capital LLC acquired a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at about $23,264,000. First Trust Capital Management L.P. bought a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter worth about $20,474,000. Hudson Bay Capital Management LP acquired a new position in shares of Drugs Made In America Acquisition II in the fourth quarter valued at approximately $19,493,000. Finally, Millennium Management LLC bought a new position in Drugs Made In America Acquisition II in the 4th quarter valued at approximately $14,850,000.

Drugs Made In America Acquisition II Company Profile

(Get Free Report)

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.